/

Empresas

Ad

No verificado

Aditxt, Inc.

Sobre qué escribimos

BiotecnologíaFarmacéuticaMedicina - VariosOncologíaSalud

62 Comunicados de prensa

Ver todos los comunicados de prensa

09/06/2026

Mercado laboral

Mercado de valores

Acciones y Obligaciones

Biotecnología

Farmacéutica

Salud

Oncología

Aditxt Signed Definitive Agreement Valuing Ignite Proteomics at Approximately $150 Million

Fuente

Editor

1.00

0

01/06/2026

Biotecnología

Farmacéutica

Salud

Oncología

Mercado laboral

Aditxt, Inc. Appoints Jeffrey M. Busch as Interim Chief Executive Officer; Founder and Former CEO of $1B NYSE Enterprise Which Delivered ~8.5% Dividends to Shareholders

Fuente

Editor

1.00

0

14/05/2026

Finanzas

Biotecnología

Salud

Farmacéutica

Oncología

Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-27 Reverse Stock Split Effective at the Open of Trading on May 18, 2026

Fuente

Editor

1.00

0

20/04/2026

Industria

Oncología

Salud

Medicina - Varios

Ciencia

Farmacéutica

Biotecnología

Dana-Farber Cancer Institute Study Demonstrates Predictive Value of Ignite Proteomics’ RPPA Platform for T-DXd (Enhertu®) Therapy in Metastatic Breast Cancer Patients

Fuente

Editor

1.00

0

19/03/2026

Ciencia

Biotecnología

Medicina - Varios

Farmacéutica

Salud

Oncología

Mercado laboral

Aditxt Subsidiary Ignite Proteomics Appoints Public Company Veteran Jeff Busch as Chief Executive Officer

Fuente

Editor

1.00

0

13/03/2026

Eventos

Mercado de valores

Ciencia

Biotecnología

Medicina - Varios

Farmacéutica

Salud

Oncología

Aditxt Acquires Ignite Proteomics to Address a Critical Challenge in Cancer Care: Optimizing Therapy Selection

Fuente

Editor

1.00

0

05/03/2026

Finanzas

Ciencia

Biotecnología

Farmacéutica

Oncología

Salud

Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-8 Reverse Stock Split Effective at the Open of Trading on March 9, 2026

Fuente

Editor

1.00

0

18/11/2025

Técnica

Salud

Finanzas

Sanidad

Asociaciones/Profesionales

Oncología

Ciencia

Software

Acciones y Obligaciones

Aditxt Provides Updates on its Growth Vision for bitXbio™, Planned Digital Asset Treasury, Pearsanta’s Planned IPO, And Evofem’s Plan to Regain a National Listing

Fuente

Editor

1.00

0

29/10/2025

Salud

Ciencia

Farmacéutica

Biotecnología

Finanzas

Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-113 Reverse Stock Split Effective at the Open of Trading on November 3, 2025

Fuente

Editor

1.00

0

27/10/2025

Sanidad

Ir de compras

Salud

Medicina - Varios

Industria

Aditxt Subsidiary Pearsanta Begins Enrollment in First Human Study of Blood-Based Diagnostic for Endometriosis, a Condition Affecting 190 Million Women Worldwide and Representing a $1.45 Billion Global Market

Fuente

Editor

1.00

0

Seguidores

0

Compatibilidad

0